Gregory Sargen

CIK: 0001227835

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TARA

Protara Therapeutics, Inc.

Director

CDMO

Avid Bioservices, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TARA
Protara Therapeutics, Inc.
Jun 15, 2026
Award(A)
Stock Option (Right to Buy)
Direct
31K shares-
TARA
Protara Therapeutics, Inc.
Jun 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
24K shares-
CDMO
Avid Bioservices, Inc.
Feb 5, 2025
Disposition(D)
Direct
36.4K shares-
CDMO
Avid Bioservices, Inc.
Dec 14, 2024
Exercise(M)
Direct
26.8K shares-
CDMO
Avid Bioservices, Inc.
Dec 14, 2024
Award(A)
Restricted Stock Units
Direct
8.1K shares-

		Type	Shares	Price		Ownership
Jun 15, 2026	TARA Protara Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	31,000	-	-	Direct
Jun 12, 2025	TARA Protara Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	24,000	-	-	Direct
Feb 5, 2025	CDMO Avid Bioservices, Inc.	Disposition(D)	36,368	-	-	Direct
Dec 14, 2024	CDMO Avid Bioservices, Inc.	Exercise(M)	26,756	-	$0	Direct
Dec 14, 2024	CDMO Avid Bioservices, Inc.	Award(A) Restricted Stock Units	8,147	-	-	Direct

1-5 of 5 transactions

About SARGEN GREGORY

SARGEN GREGORY (SEC CIK 0001227835) files insider reports with the SEC as Director of Protara Therapeutics, Inc. (TARA) and Director of Avid Bioservices, Inc. (CDMO).

Signal8 holds 4 ownership filings by SARGEN GREGORY, all Form 4s, filed between Dec 17, 2024 and Jun 16, 2026. Those filings report 5 transactions, from Dec 14, 2024 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SARGEN GREGORY's filings is in NEW YORK, NY.

Recent filings by SARGEN GREGORY

Jun 15, 2026: Grant or award of TARA derivative securities (Form 4, code A).
Jun 12, 2025: Grant or award of TARA derivative securities (Form 4, code A).
Feb 5, 2025: Disposition to issuer transaction of CDMO shares (Form 4, code D).
Dec 14, 2024: Option exercise of CDMO shares (Form 4, code M).
Dec 14, 2024: Grant or award of CDMO derivative securities (Form 4, code A).

Other insiders filing for Protara Therapeutics, Inc. (TARA)

Shefferman Jesse, CEO and President
Levy Richard S, Director
Solomon Michael Edward, Director
Smith Cynthia, Director
Huang Jane, Director
GARCEAU ROGER, Director

How to read Form 4 transaction codes